CORONAVIRUS

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

Takaki Asano1, Bertrand Boisson1,2,3,†, Fanny Onod1,2,4, Daniela Matuozzo2,5,6, Marcela Moncada-Velez9, Majistor Raj Luxman Maglorius Renkilä11,2,3, Peng Zhang7, Laurent Meertens8, Alexandre Bolze9, Marie Materna2,5,6, Sarantis Korniotis6, Adrian Gervais2,3, Estelle Talouarn2,3, Benedetta Bigio3, Yoann Seeleutner2,4, Kaya Bilgůr2,5, Yu Zhang6,9, Anna-Lena Neehus2,3, Masato Ogishi1, Simon J. Pelham1, Tom Le Voyer2,3, Jérémie Rosain2,3, Quentin Philippot2,3, Pere Soler-Palacín10,11,12, Roger Colobran12,13,14, Andrea Martin-Nalda10,11,12, Jacques G. Rivière10,11,12, Yacine Tandjaoui-Lambiotte15,16, Khalil Chaibi17,18, Mohammad Shahrooei19,20, Ilad Alavi Darazam19,21,22, Nasrin Alipour Olyaei19,20, Davood Mansouri23,24,25, Nevin Hatipoğlu26, Figen Palabiyik26, Tayfun Özcelik27, Giuseppe Novelli28, Antonio Novelli29, Giorgio Casari30,31, Alessandro Aiuti30,32, Paola Carrera31, Simone Bondesan31, Federica Barzaghi32, Patrizia Rovere-Querini30,33, Cristina Tresoldi33, Jose Luis Franco35, Julian Rojas35, Luis Felipe Reyes36, Ingrid G. Bustos36, Andres Augusto Arias37,35,37, Guillaume Morelle38, Kyheng Christèle1, Jesus Troya39, Laura Planas-Serra40,41, Agatha Schlüter40,41, Marta Gut42, Aurora Pujol40,41,43, Luis M. Allende44,45, Carlos Rodriguez-Gallego46,47, Carlos Flores48,49,50,51, Oscar Cabrera-Marante44, Daniel E. Pleguezuelo44, Rebeca Pérez de Diego42, Sevgi Kekes43, Gokhan Aytekin44, Ozge Metin Akcan53, Yenat T. Brycecon42, Peter Bergman46,60, Petter Brodin47, Daniel Smole48, C.I. Edvard Smith59,60, Anna-Carin Norlin60, Tessa M. Campbell49,62, Laura E. Covill55,60, Lennart Hammarström61, Qiang Pan-Hammarström61, Hassan Abbolhasanni62,63, Shrikant Mane65, Manar Ata64, Fatima Al Ali64, Taushif Khan64, Andras N. Spaan1,65, Clifton D. Talagan66,67, Paolo Bonfanti68, Andrea Biondi69,9, Sarah Tubiana70,71, Charles Burdet70,72, Robert Nussbaum73, Amanda Kahn-Kirby73, Andrew L. Snow74, COVID Human Genetic Effort7, COVID-STORM Clinicians, COVID Clinicians, Imagine COVID Group, French COVID Cohort Study Group, CoV-Contact Cohort, Amsterdam UMC Covid-19 Biobank, NIAID-USUHS COVID Study Group, Jacinta Bustamante1,2,3,75, Anne Puell1,2,3, Sophie Stephanosse-Dupuis1,2,3, Shen-Ying Zhang1,2,3, Viviën Béziat1,2,3, Richard P. Lifton7,76§, Paul Bastard2,3, Luigi D. Notarangelo6,9,4, Laurent Abel1,3,21, Helen C. Su5,7,77, Emmanuelle Jouanguy1,2,3, Ali Amara44, Vassili Soumelis6,7,68, Aurélie Cobati2,3,5,8, Qian Zhang9, and Jean-Laurent Casanova1,2,3,79,†

1. St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA. 2. Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France. 3. University of Paris, Imagine Institute, Paris, France. 4. Laboratory of Genomes & Cell Biology of Disease, INSERM U944, CNRS UM2712, University of Paris, Research Institute of Saint-Louis, Saint-Louis Hospital, Paris, France. 5. Helix, San Mateo, CA, USA. 6. University of Paris, INSERM U976, F-75006 Paris, France. 7. Yale Center for Genome Analysis and Department of Genetics, Yale School of Medicine, New Haven, CT, USA. 8. Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, NIH, Bethesda, MD, USA. 9. NIAID Clinical Genomics Program, NIH, Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, NIAID, NIH, Bethesda, MD, USA. 10. Infection in Immunocompromised Pediatric Patients Research Group, Vall d’Hebron Research Institute (VHIR), Vall d’Hebron University Hospital (HUVH), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Catalonia Spain. 11. Pediatric Infectious Diseases and Immunodeficiencies Unit, Vall d’Hebron University Hospital (HUVH), Vall d’Hebron Research Institute (VHIR), Vall d’Hebron Barcelona Hospital Campus, Autonomous University of Barcelona (UAB), Barcelona, Catalonia, Spain. 12. Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Barcelona, Catalonia, Spain. 13. Diagnostic Immunology Group, Vall d’Hebron Research Institute (VHIR), Vall d’Hebron University Hospital (HUVH), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Catalonia, Spain. 14. Immunology Division, Genetics Department, Vall d’Hebron University Hospital (HUVH), Vall d’Hebron Barcelona Hospital Campus, Autonomous University of Barcelona (UAB), Barcelona, Catalonia, Spain. 15. AP-HP, Avicenne Hospital, Intensive Care Unit, Bobigny, France. 16. INSERM U1272, Hypoxia & Lung, Bobigny, France. 17. Anesthesiology and Critical Care Medicine Department, APHP, Avicenne Hospital, Bobigny, France. 18. Common and Rare Kidney Diseases, Serbonne University, INSERM UMR-S 1155, Paris, France. 19. Specialized Immunology Laboratory of Dr. Shahrooei, Sina Medical Complex, Ahvaz, Iran. 20. Department of Microbiology and Immunology, and Diagnostic Immunology, KU Leuven, Leuven, Belgium. 21. Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 22. Department of Infectious Diseases and Tropical Medicine, Loughman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 23. Department of Clinical Immunology and Infectious Diseases, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 24. The Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Mash Daneshvari Hospital, Shahid Beheshti, University of Medical Sciences, Tehran, Iran. 25. Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti, Iran. 26. Pediatric Infectious Diseases Unit, Bakirköy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. 27. Department of Molecular Biology and Genetics, University of Bilkent, Bilkent-Ankara, Turkey. 28. Department of Biomedicine and Prevention, University of Rome “Tor Vergata,” Rome, and Neourmed Institute, IRCCS, Pozzilli (IS), Italy. 29. Laboratory of Medical Genetics, Translational Cytogenomics Research Unit, Bambino Gesù Children Hospital, IRCCS, Rome, Italy. 30. Vita-Salute San Raffaele University, Milan, Italy. 31. Clinical Genomics, IRCCS San Raffaele Scientific Institute, Milan, Italy. 32. San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) and Pediatric Immunohematology Unit and BMT Program, IRCCS San Raffaele Scientific Institute, Milan, Italy. 33. Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. 34. Molecular Hematology Unit, IRCCS Ospedale San Raffaele, Milan, Italy. 35. Primary Immunodeficiencies Group, Department of Microbiology and Parasitology, School of Medicine, University of Antioquia, Medellín, Colombia. 36. Universidad de La Sabana, Chia, Colombia. 37. School of Microbiology, University of Antioquia UdeA, Medellín, Colombia. 38. Department of General Pediatrics, Hôpital Bicêtre, AP-HP, University of Paris Saclay, Le Kremlin-Bicêtre, France. 39. Department of Internal Medicine, Infanta Leonor University Hospital, Madrid, Spain. 40. Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. 41. Center for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Spain. 42. CNAG-CRG, Centre for...
INTRODUCTION

Interindividual clinical variability in the course of SARS-CoV-2 infection is vast, ranging from silent infection to lethal disease (1). The greatest risk factor for life-threatening COVID-19 pneumonia is age, with a doubling in risk every five years from the age of five years onward, and a sharp rise after the age of 65 years (2, 3). Other epidemiological risk factors, including common genetic variants, have only modest effects, with odds ratios (ORs) < 2 and typically < 1.5 (2). One intriguing observation is the approximately 1.5 times higher risk in men, which seems to be age-independent (2–4). The COVID Human Genetic Effort consortium (www.covidhge.com) has enrolled an international cohort of patients, with the aim of investigating genetic and immunological causes of life-threatening COVID-19 pneumonia. We previously tested the hypothesis that critical influenza and critical COVID-19 can be allelic (5–7), and showed that life-threatening COVID-19 pneumonia can be caused by rare autosomal inborn errors of type I IFN immunity and autoantibodies against these cytokines underlie at least 10% of critical COVID-19 pneumonia cases. We report very rare, biochemically deleterious X-linked TLR7 variants in 16 unrelated male individuals aged 7 to 71 years (mean: 36.7 years) from a cohort of 1,202 male patients aged 0.5 to 99 years (mean: 52.9 years) with unexplained critical COVID-19 pneumonia. None of the 331 asymptotically or mildly infected male individuals aged 1.3 to 102 years (mean: 38.7 years) tested carry such TLR7 variants (p = 3.5 × 10^{-5}). The phenotypes of five hemizygous relatives of index cases infected with SARS-CoV-2 include asymptomatic or mild infection (n=2, 5 and 38 years), or moderate (n=1, 5 years), severe (n=1, 27 years), or critical (n=1, 29 years) pneumonia. Two boys (aged 7 and 12 years) from a cohort of 262 male patients with severe COVID-19 pneumonia (mean: 51.0 years) are hemizygous for a deleterious TLR7 variant. The cumulative allele frequency for deleterious TLR7 variants in the male general population is < 6.5x10^{-4}. We also show that blood B cell lines and myeloid cell subsets from the patients do not respond to TLR7 stimulation, a phenotype rescued by wild-type TLR7. The patients’ blood plasmacytoid dendritic cells (pDCs) produce low levels of type I IFNs in response to SARS-CoV-2. Overall, X-linked recessive TLR7 deficiency is a highly penetrant genetic etiology of critical COVID-19 pneumonia, in about 1.8% of male patients below the age of 60 years. Human TLR7 and pDCs are essential for protective type I IFN immunity against SARS-CoV-2 in the respiratory tract.
inborn errors of autosomal genes controlling TLR3- and IRF7-dependent type I interferon (IFN) immunity (8). These disorders were found in 23 men and women aged 17 to 77 years (mean: 48 years). Remarkably, four unrelated patients aged 25 to 50 years had autosomal recessive IFNAR1 (n=2) or IRF7 (n=2) deficiency. These patients had no previous history of severe viral illness, including influenza pneumonia, implying that these genetic disorders unexpectedly show incomplete penetrance for critical influenza. These findings revealed that TLR3- and IRF7-dependent type I IFN immunity is essential for host defense against SARS-CoV-2 infection in the respiratory tract.

We also found pre-existing neutralizing auto-Abs against type I IFN in at least 10% of the patients from this cohort (9). These auto-Abs were found in 101 patients, mostly men (95%), and older members of the cohort, which included patients with inborn errors, as they were aged 25 to 87 years (mean: 65 years). These findings have been replicated in five other cohorts (10–15). These auto-Abs predated SARS-CoV-2 infection and were highly likely to be causal for critical COVID-19 pneumonia, because (i) they were found in samples drawn before infection in some patients (9), (ii) they were found in about 0.3% of the general population before the age of 65 years (9), (iii) they were absent from patients with asymptomatic or paucisymptomatic (mild) SARS-CoV-2 infection (9), (iv) they were of childhood onset in patients with various disorders — including autoimmune polyendocrinopathy type I (APS-1) — known to be at very high risk of life-threatening COVID-19 (16), and (v) they have been shown to underlie a third of adverse reactions to the live attenuated viral vaccine for yellow fever (17). Collectively, these studies showed that type I IFNs are essential for protective immunity to SARS-CoV-2 in the respiratory tract, but are otherwise surprisingly redundant. Auto-Abs against type I IFNs also provide a first explanation for both the biased sex ratio and the higher risk of critical COVID-19 in patients over the age of 65 years. Here, we tested the hypothesis that critical and unexplained COVID-19 pneumonia in men may be due to rare variants on the X-chromosome.

RESULTS

Enrichment for very rare TLR7 non-synonymous variants in male patients

We tested the hypothesis of genetic homogeneity for X-linked recessive disorders in male individuals with critical COVID-19 pneumonia (hereafter referred to as “patients”, see Materials and Methods). We analyzed an international cohort of 1,202 unrelated male patients aged 6 months to 99 years (mean: 52.9 years) that possessed no known inborn errors of TLR3- and IRF7-dependent type I IFN immunity (8) and without neutralizing auto-Abs against type I IFNs (9) (reported in an accompanying paper (79)) (Table S1). We also analyzed 331 asymptomatic or paucisymptomatic infected male subjects aged 1.3 to 102 years (mean: 38.7 years), with positive results for PCR and/or serological screening for SARS-CoV-2 infection (hereafter referred to as “controls”) (Table S1). We sequenced the exomes (n=1,035) or genomes (n=498) of these patients and controls. We selected in-frame and out-of-frame non-synonymous variants of protein-coding exons that are very rare, that is, with a minor allele frequency (MAF) below 10−4 in the full gnomAD database (v2.1.1) containing sequences from both male and female individuals. We compared the proportions of patients and controls carrying at least one qualifying variant, by Firth bias-corrected logistic regression adjusted for age and ethnicity (18) (Fig. S1A). We found non-synonymous variants in at least five patients for 226 of 731 genes on the X chromosome, resulting in a Bonferroni-corrected significance threshold of 2.2x10−4 (Data file S1). TLR7 was the highest ranked of these genes (uncorrected P-value = 3.5x10−5) and the only gene that remained significant after correction for multiple testing (corrected P-value = 7.8x10−6), with 21 unrelated patients carrying one very rare (n=4 patients), two very rare (n=1 patient), or one private (n=16 patients) non-synonymous variant (Fig. 1A, Table S2). One variant (L988S) was recurrent, found in three patients, including a patient carrying two very rare variants (M854I;L988S). No such variants were found in the controls. The same analysis performed on very rare (MAF<10−6) synonymous TLR7 variants showed no enrichment in patients (one carrier) relative to controls (three carriers).

Human TLR7 is an endosomal receptor of ribonucleic acids expressed by B cells and myeloid subsets (19–23), the stimulation of which in plasmacytoid dendritic cells (pDCs) results in the production of large amounts of type I IFN (24–26). We observed no significant enrichment for coding non-synonymous variants of the X-linked gene TLR8 (P-value = 0.68, Table S2), the product of which, TLR8, is endosomal and can be stimulated by some synthetic TLR7 agonists, with an expression pattern and signaling pathway overlapping those of TLR7 (27, 28). Unlike TLR7, TLR8 is expressed on granulocytes but not on pDCs, possibly accounting for its gain-of-function mutations underlying a phenotype different from type I interferonopathies (29–31). Overall, we found an enrichment in very rare or private non-synonymous TLR7 variants among the male patients with critical COVID-19 pneumonia (n=21, 1.7%) of our cohort (n=1,202), including one man over the age of 60 years.

The TLR7 mutant alleles of 16 of the 21 unrelated patients with critical COVID-19 pneumonia are biochemically deleterious

The 21 unrelated patients carried 20 different TLR7 alleles. We expressed the 20 TLR7 mutant proteins in human embryonic kidney (HEK) 293T cells, which have no endogenous TLR7 and TLR8 expression (32), by transient transfection with the corresponding cDNAs. Immunoblotting of
protein extracts with a TLR7-specific mAb showed an absence of TLR7 protein for p.N158Tfs*11 and p.L227fs* and the presence of truncated proteins for K684* and F670Lfs*8 (Fig. 1B). The other mutant TLR7 proteins were produced in normal amounts (Fig. 1B). We tested their function by cotransfection with an NF-κB-specific luciferase reporter. We measured luciferase activity upon stimulation with R848, an agonist of both TLR7 and TLR8 (Fig. 1C). Twelve of the 20 alleles were loss-of-function (LOF) (including I988S in two patients, and M854I;L988S in another), three (p.L372M, p.I657T and p.P715S) were hypomorphic (activity < 25%), and the remaining five were neutral (Fig. 1C, Data file S2). Similar results were obtained with imiquimod and CL264, two TLR7-specific agonists (Fig. S1B, S1C). We also tested eight other private alleles in the general population (141,456 individuals in gnomAD v2.1) that had been reported in men or had a general MAF > 10−5 (Fig. 1D and Fig. S1E, Data file S2). In total, 96 of these variants were missense and three were in-frame small deletions; 10 were weakly expressed, whereas the others had normal levels of expression (Fig. S1F, Data file S2). One variant was a small deletion creating a frameshift found in one man and resulting in an absence of protein production (Fig. S1F, Data file S2). Seven of the 100 variants were LOF and 15 were hypomorphic (activity < 25%) (Data file S2). We then analyzed 262 other, unrelated men for TLR7 deficiency in the general population. Each of these 24 deleterious variants had an individual MAF < 1.3x10−4 in men and their cumulative MAF in men was 6.5x10−4 (Data file S2, Table S3). The cumulative MAF of strictly LOF TLR7 alleles (excluding hypomorphic alleles) in men is about 2.2x10−4 (Data file S2). Overall, we found 12 LOF and three hypomorphic TLR7 alleles in 16 unrelated men with critical COVID-19 pneumonia, whereas deleterious alleles were not found in men with asymptomatic or paucisymptomatic infection. Moreover, deleterious TLR7 alleles in the general population had individual and cumulative MAF values in men of < 1.3x10−4 and < 6.5x10−4, respectively (Fig. 1E, Data file S2). The rarity of TLR7 deficiency in the general population is consistent with TLR7 deficiency underlying critical COVID-19. Collectively, these findings suggest that X-linked recessive (XR) TLR7 deficiency is a genetic etiology of life-threatening COVID-19 pneumonia in men.

**High clinical penetrance of inherited TLR7 deficiency in the patients’ families**

The 16 patients were of three major ethnic origins, as confirmed by principal component analysis (PCA) of their exomes or genomes (35), and they were resident in seven countries (France n=2, Spain n=3, Italy n=3, Turkey n=2, Sweden n=1, Iran n=4, Colombia n=1) (Fig. 2A, 2C, Fig. S1, Table 1, Data file S3). The patients were hospitalized for critical COVID-19 between March 2020 and June 2021. Blood samples (diluted 1/10) from these 16 patients contained no auto-Abs neutralizing 10 ng/mL IFN-α or IFN-ω (9) (79). The patients were aged 7 to 71 years and their mean age was lower than that of the total cohort (mean age of 34.4 years, versus 52.9 years for the total cohort, in which age ranged from 0.5 to 99 years). TLR7-deficient patients accounted for about 1.8% of the patients below the age of 60 years (15 patients) and 1.3% of the entire cohort (16 patients). Two patients died and 14 survived (Fig. 2A, Table 1). Sanger sequencing of the TLR7 locus in the relatives of these patients identified the deleterious alleles in 16 heterozygous women from eleven families and seven hemizygous men from seven families (Fig. 2A). Based on the ten DNA samples available from the patients’ mothers, only one of the TLR7 variants (L372M) was de novo in the index case. Five of the seven hemizygous relatives of the index case had antibodies against SARS-CoV-2 (Fig. 2A, Data file S3). One 29-year-old adult (Kindred J, P11) was hospitalized for critical pneumonia, and another 27-year-old adult (L.II.3) was hospitalized for severe pneumonia (with low-flow oxygen (<6L/min)). The remaining three were two five-year-old boys, one of whom had been hospitalized for moderate COVID-19 pneumonia (without oxygen therapy) (D.II.2), the other having no relevant clinical history (M.II.2), and one 38-year-old adult with no relevant clinical history (E.II.4) (Data file S3). The other two male carriers did not report SARS-CoV-2 infection and had negative serological results for antibodies against the SARS-CoV-2 S and N proteins.

**Inherited TLR7 deficiency in patients with severe COVID-19 pneumonia**

Given these results, we also analyzed 262 other, unrelated male patients with severe (but not critical) COVID-19 pneumonia (mean age: 51.0 years). We identified a new private LOF variant (p.N75H) in two male patients from two Turkish families (P18 and P19), aged 12 and 7 years, respectively, who were subsequently found to be fourth-degree relatives (Fig. 1B, 1C, 1D, Fig. 2B, Fig. S1B, Data file S2, Data file S3). Their
mothers are heterozygous for this variant. The clinical penetrance of critical COVID-19 in men is therefore high, but not complete, and TLR7 deficiency can also underlie severe COVID-19. The absence of biochemically deleterious TLR8 variants in our cohort of patients with critical COVID-19 (Fig. S2) and its lack of expression on pDCs suggest that TLR8 is not a modifier of the SARS-CoV-2-related clinical phenotype of TLR7 deficiency, although it is adjacent to TLR7 on the X chromosome and can be stimulated by overlapping molecules. Perhaps more relevant to the understanding of the incomplete penetrance is the age of the patients. Of the 23 male patients carrying deleterious alleles of TLR7 infected with SARS-CoV-2, the 20 patients who developed severe \( (n=3) \) or critical \( (n=17) \) COVID-19 were aged 7-71 years (mean: 32.4 years) whereas the three patients who developed asymptomatic, mild, or moderate infection were younger: 5, 5, and 38 years (mean: 16 years). Blood pDC counts decrease with age \( (36-38) \), and this may contribute to the apparent increase in penetrance with age. In addition, a VirScan study of the serum samples of five index cases and three TLR7 hemizygous relatives revealed prior infection with diverse viruses (Fig. S3). None had previously been hospitalized for a severe viral illness, including influenza pneumonia. This cohort of patients thus suggests that TLR7 deficiency does not underlie severe disease caused by common viral infections other than SARS-CoV-2, or if so, with lower penetrance.

**Deleterious TLR7 alleles abolish B cell responses to TLR7 agonists**

As a first approach to testing the impact of deleterious TLR7 alleles in the patients’ cells, we tested Epstein-Barr virus-transformed B cell lines (EBV-B cells) from healthy controls and patients carrying the hemizygous p.K684* (P12) or p.H781L (P14) variants. The endogenous expression of the p.H781L TLR7 protein was normal, whereas p.K684* generated a truncated protein (Fig. 2D). In response to agonists of TLR7 (imiquimod) or TLR7 plus TLR8 (R848), the EBV-B cell lines carrying these two mutations failed to produce TNF (Fig. 2E, Fig. S4A, S4B). The lentiviral transduction of these TLR7-deficient EBV-B cells (from P12 and P14) with a WT TLR7 cDNA was unsuccessful, despite numerous attempts, and this was also the case for control EBV-B cells, perhaps because the overproduction of TLR7 is toxic in B cells \( (39) \). Consistent with this view, we were able to express this cDNA in IRAK4- or MyD88-deficient EBV-B cells. We therefore investigated whether the addition of an IRAK4 inhibitor (PF06650833) would permit the expression of WT TLR7 in control and TLR7-mutated EBV-B cells. This approach was successful, and WT TLR7 expression restored responses to TLR7 agonists (after removal of the inhibitor) (Fig. 2F, Fig. S4C). Hemizygosity for LOF TLR7 alleles thus abolished responses to TLR7 stimulation in EBV-B cells, a phenotype that was rescued by WT TLR7 expression. Collectively, these findings further suggest that XR TLR7 deficiency is a genetic etiology of severe/critical COVID-19 pneumonia.

**The TLR7-mutated patients’ myeloid cells, including pDCs, do not respond to TLR7 agonists**

Human TLR7 is known to be expressed and functional only in leukocyte subsets: plasmacytoid and classical dendritic cells (pDCs and mDCs), monocytes (classical, intermediate, and non-classical), and B cells \( (27, 32, 40) \). TLR8 is expressed in mDCs but not pDCs, monocytes but not B cells, and neutrophils (unlike TLR7) \( (27, 32, 40) \). Neither TLR7 nor TLR8 mRNAs have been detected in the lung or pulmonary epithelial cells \( (41) \). Deep immunophenotyping by CyTOF in seven patients with TLR7 deficiency revealed no major abnormalities in 18 peripheral blood leukocyte subsets, including pDCs, mDCs, monocytes, and B cells (Fig. 3A, Fig. S5A). We previously reported inherited IRF7 deficiency in a child with critical influenza pneumonia \( (5) \) and two unrelated adults with critical COVID-19 pneumonia \( (8) \). This defect disrupts the amplification of type I IFNs in all cell types, including pDCs, which are normally the main producers of type I IFN upon blood cell stimulation with TLR7 agonists or viruses, due to their constitutive expression of IRF7 \( (27, 42-44) \). We hypothesized that TLR7 deficiency in pDCs impairs the production of type I IFN by these cells in response to ssRNA. We confirmed that TLR7 was expressed on pDCs, and that TLR8 was not (Fig. 3B, S5B, S5C). We measured the production of type I IFNs by purified leukocyte subsets (pDCs, mDCs, monocytes, B cells, T cells), in response to TLR7, TLR8 and TLR9 agonists (Fig. 3C, Fig. S5D). We confirmed that pDCs produced 100-1,000 times more type I IFN per cell than other leukocyte subsets upon TLR7 stimulation (Fig. 3C, Fig. S5D). We purified pDCs from P8 and P14 and analyzed their production of type I IFNs in response to CL264 and class C CpG oligonucleotide (CpG-c), relative to that of pDCs from healthy relatives, using a cytometric bead array (CBA) (Fig. 3D). pDCs from P8 and P14 did not produce type I IFNs (or IL-6) upon stimulation with a TLR7 agonist, whereas they responded to a TLR9 agonist (Fig. 3D). Moreover, agonist-induced up-regulation of PD-L1 and CD80 defines the maturation of pDCs into the S1 (PD-L1high/CD80low), S2 (PD-L1high/CD80high), and S3 (PD-L1high/CD80high) subsets \( (45) \). This maturation was not observed in the pDCs of P8 and P14, but was detected in the pDCs of healthy relatives and controls (Fig. 3E, Fig. S5E). Thus, pDCs from patients with TLR7 mutations do not respond to TLR7 agonists in terms of maturation into specialized subsets and type I IFN production.

**The TLR7-deficient patients’ pDCs respond poorly to SARS-CoV-2**

A plausible mechanism accounting for the severity of COVID-19 in TLR7-deficient patients is the impairment of type I IFN production by pDCs upon stimulation with SARS-CoV-2, which can enter these cells, but cannot replicate
productively within them (45, 46). Indeed, we previously showed that the activation of human pDCs by SARS-CoV-2 depends on IRAK4 and UNC-93B, but not TLR3 (45). We tested the hypothesis that TLR7 is an essential pDC sensor of SARS-CoV-2, upstream from IRAK4 and UNC-93B, by infecting pDCs and pDC-depleted leukocytes from healthy controls and TLR7-deficient patients with SARS-CoV-2 for 24 hours. Control pDC-depleted leukocytes infected with SARS-CoV-2 displayed no significant up- or down-regulation of gene expression (Fig. S6A). By contrast, transcriptomic analysis showed a strong up-regulation of the type I IFN transcriptional module in pDCs from healthy controls, which was greatly reduced in pDCs from TLR7-deficient patients (Fig. 4A). Induction of the 17 type I IFN genes in pDCs from TLR7-deficient patients was 10 to 100 times weaker than that in pDCs from healthy individuals (Fig. 4B, S6B). We also analyzed the functional specialization of pDC subsets (S1-, S2-, and S3-pDC subsets) in response to SARS-CoV-2 activation (45, 47). pDCs from P14 cultured with SARS-CoV-2 for 24 hours displayed abnormally low levels of maturation into the S1-subset—the pDC subset principally responsible for IFN-α production upon SARS-CoV-2 infection (Fig. S6C). Finally, we evaluated the amount of type I IFNs secreted by SARS-CoV-2-infected pDCs. All 13 individual IFN-α forms were produced in significantly smaller amounts by TLR7-deficient pDCs than by control pDCs (Fig. 4C, S6D). However, IFN-α production by TLR7-deficient pDCs upon SARS-CoV-2 infection was impaired, but not entirely abolished, as in UNC-93B- or IRF7-deficient pDCs (8, 45), implying that there are also TLR7-independent sensors of SARS-CoV-2 in pDCs and suggesting that TLR9 is involved. The TLR7-deficient pDCs’ normal response to TLR9 agonists (Fig. 3D, 4A, 4B, S6D) is consistent with this hypothesis, while also suggesting that genetic or epigenetic variations of TLR9 responses may contribute to the apparently age-dependent penetrance of TLR7 deficiency. Thus, SARS-CoV-2 triggers type I IFN induction in pDCs in a manner that is dependent on TLR7, but not exclusively so. As pDCs are normally the main leukocytes producing type I IFN in such conditions, and type I IFN is essential for protective immunity to SARS-CoV-2 (8, 9), these findings suggest that XR TLR7 deficiency underlies critical or severe COVID-19 pneumonia by disrupting TLR7-and pDC-dependent type I IFN production.

DISCUSSION

We report XR TLR7 deficiency as a genetic etiology of severe/critical COVID-19 pneumonia in 20 unrelated male patients, aged 7 to 71 years, from seven countries. Only one of these 20 patients (5%) was older than 60 years, consistent with our previous observation that only five of 23 patients (21.7%) with inborn errors of TLR3-dependent type I IFN immunity were older than 60 years (8). This suggests that these genetic defects are mostly found in the youngest patients. This contrasts with the situation for auto-Abs against type I IFNs, which are found mostly in patients over the age of 60 years (8, 9) (79). Importantly, patients with these auto-Abs do not overlap with those bearing inborn errors of TLR3- or TLR7-dependent type I IFNs. TLR7-deficient patients accounted for about 1.8% of the unrelated male patients with critical COVID-19 pneumonia below the age of 60 years in our cohort and accounted for 1.3% of the total cohort. This proportion remained around the same when severe COVID-19 pneumonia was also taken into account (1.7% males below 60 years; 1.2% of all the male patients in the total cohort). We also found that six of the 12 previously reported patients with a TLR7 variant had TLR7 deficiency (33, 34). It would be interesting to test experimentally the undisclosed TLR7 variants reported to be enriched in another study (48). Our discovery provides an explanation for the higher risk of severe and critical disease in men than in women under the age of 60 years, complementing our previous observation of a much higher frequency of neutralizing auto-Abs against type I IFNs in men than in women with critical COVID-19 pneumonia for patients over the age of 60 years (9).

Previous reports of patients with critical COVID-19 pneumonia due to inborn errors of TLR3-dependent type I IFN immunity (8), including autosomal recessive IRF7 or IFNAR1 deficiency (5, 6), or due to auto-Abs neutralizing type I IFNs (9, 11–14, 16, 17), strongly suggest that critical disease in TLR7-deficient patients is a consequence of impaired type I IFN production upon SARS-CoV-2 infection. The absence of biochemically deleterious X-linked TLR8 variants in our cohort of patients suggests that TLR8 is not essential for host defense against SARS-CoV-2. This is consistent with the modest capacity of TLR8 to induce type I IFN and its lack of expression on pDCs (27), and with the inflammatory phenotype of TLR8 gain-of-function mutations, which do not underlie a type I interferonopathy (29–31). Patients with inherited IRAK4 or MyD88 deficiency, whose cells do not respond to the stimulation of IL-1Rs and TLRs other than TLR3, including TLR7, have not been reported to display any severe viral illness over the almost 20 years since the discovery of IRAK-4 deficiency (49–52). Moreover, UNC-93B-deficient pDCs produced normal amounts of type I IFN in response to seasonal influenza virus (5). This was intriguing, as strong negative selection operates at the human TLR7, TLR8, and TLR9 loci (49, 53). Our study provides an answer to this riddle, by establishing that TLR7 is essential for protective immunity to SARS-CoV-2. Patients with IRAK4, MyD88, or UNC93B deficiency are now predicted to be vulnerable to SARS-CoV-2 (54–56). Critical COVID-19 and seasonal influenza can be caused by inborn errors of TLR3-dependent type I IFN immunity (3–8), but susceptibility to these infections is not allelic at the TLR7 locus. It is, nevertheless, tempting to speculate that TLR7 might also be essential for host defense against more virulent,
pandemic viruses, including both coronaviruses and influenza viruses.

Through the discovery of the essential nature of TLR7 for the induction of type I IFN in response to SARS-CoV-2, our study also reveals the essential role of human pDCs in host defense. The constitutively high levels of IRF7 in these cells make them the most potent producers of type I IFN in the blood, and perhaps in the entire human body, and this has long suggested a possible key role in antiviral immunity (25). However, the essential and redundant roles of this leukocyte subset have yet to be determined, in the absence of human pDC-specific deficiencies causally underlying a clinical phenotype. It has long been suspected, but never proved, that pDCs are essential for host defense in natural conditions (26, 57–59). Inherited IRF7 deficiency, which underlies critical influenza or COVID-19 pneumonia, disrupts the production of type I IFNs not only by pDCs (5, 8), but also by all other cell types, including pulmonary epithelial cells (5). Likewise, patients with GATA2 deficiency, who are prone to critical influenza (60), lack pDCs, but these patients also lack many other blood cell subsets (61–64). Inherited IFNAR1 deficiency underlies critical COVID-19 probably due to its broad cellular impact (5, 6, 8). By contrast, inborn errors of the TLR3 pathway underlie critical influenza or COVID-19 pneumonia by impairing the production of type I IFNs by cells other than pDCs, such as pulmonary epithelial cells (5–8, 65). Our study indicates that pulmonary epithelial cells are not sufficient for host defense against SARS-CoV-2, as these cells do not express TLR7. Inborn errors of TLR7 are pathogenic by impairing the production of type I IFNs by blood pDCs, which are unique in their production of large amounts of both TLR7 and IRF7 (66, 67). pDCs express other viral sensors, including TLR9 (for DNA), MDA5 and RIG-I (for dsRNA) (68), but TLR7 deficiency impairs their capacity to produce large enough amounts of type I IFN in response to SARS-CoV-2 in the respiratory tract. Overall, by disrupting pDC-dependent type I IFN production, XR TLR7 deficiency accounts for at least 1% of cases of life-threatening COVID-19 pneumonia in men under 60 years.

MATERIALS AND METHODS

Study design

We searched for X-linked inborn errors of immunity in male patients with critical SARS-CoV-2 pneumonia. We screened our WES database of 1,202 male patients with critical SARS-CoV-2 pneumonia (‘patients’) and 331 male subjects with asymptomatic or paucisymptomatic infection (‘controls’). We tested the association of X-linked genes with critical SARS-CoV-2 pneumonia using a Firth bias-corrected logistic regression model including the first five principal components of the PCA to account for the ethnic heterogeneity of the cohorts and age in years. We then tested the activity of TLR7 variants in transduced cell lines and of TLR7 genotypes in hemizygous patients’ cell lines. Lastly, we tested the patients’ pDCs for their response to both TLR7 agonists and SARS-CoV-2.

Cohort recruitment and consent

This study included 1,202 male patients with life-threatening COVID-19 pneumonia, defined as patients with pneumonia who developed critical disease, whether pulmonary with high-flow oxygen (> 6L/min) or mechanical ventilation (CPAP, BIPAP, intubation), septic shock, or any other type of organ damage requiring ICU admission. This study also included patients with severe COVID-19 pneumonia, defined as hospitalized patients with pneumonia that required low-flow oxygen (<6L/min); moderate COVID-19 pneumonia, defined as patients with pneumonia but did not require oxygen therapy; and mild COVID-19, defined as patients with mild upper respiratory symptoms but without pneumonia. Patients who developed Kawasaki-like syndrome were excluded. The age of the patients ranged from 0.5–99 years, with a mean age of 52.9 years (SD 16.4 years). Asymptomatic or paucisymptomatic individuals (n = 331) were recruited on the basis of positive PCR or serological tests for SARS-CoV-2 in the absence of symptoms. These individuals were close contacts of patients or were recruited after clinical screening. The age of the asymptomatic or paucisymptomatic individuals ranged from 1.3–102 years, with a mean age of 38.7 years (SD: 17.2 years).

All the enrolled subjects provided written informed consent and were collected through protocols conforming to local ethics requirements. For patients enrolled in the French COVID cohort (clinicaltrials.gov NCT04262921), ethics approval was obtained from the CPP IDF VI (ID RCB: 2020-A00256-33) or the Ethics Committee of Erasme Hospital (P2020/203). For subjects enrolled in the COV-Contact study (clinicaltrials.gov NCT04259892), ethics approval was obtained from the CPP IDF VI (ID RCB: 2020-A00280-39). For patients enrolled in the Italian cohort, ethics approval was obtained from the University of Milano-Bicocca School of Medicine, San Gerardo Hospital, Monza – Ethics Committee of the National Institute of Infectious Diseases Lazzaro Spallanzani (84/2020) (Italy), and the Comitato Etico Provinciale (NP 4000 – Studio CORONAlab). STORM-Health care workers were enrolled in the STudio OsseRiazionale sullo screening dei lavoratori ospedalieri per COVID-19 (STORM-HCW) study, with approval from the local IRB obtained on June 18, 2020. Patients and relatives from San Raffaele Hospital (Milan) were enrolled in protocols COVID-BioE/Gene-COVID and, for additional studies, TIGET-06, which were approved by local ethical committee. For patients enrolled in Spain, the study was approved by the Committee for Ethical Research of the Infanta Leonor University Hospital, code 008-20, Committee for Ethical Research of the University Hospital 12 de Octubre, code 16/368 and the Bellvitge University Hospital.
code PR127/20, the University Hospital of Gran Canaria Dr. Negrín code 2020-200-1 COVID-19 and the Vall d’Hebron University Hospital, code PR(AM)388/2016. Anonymized samples were sequenced at the NIADR through USUHS/TAGC under non-human subject research conditions; no additional IRB consent was required at the NIH. For patients enrolled in the Swedish COVID cohort, ethics approval was obtained from the Swedish Ethical Review Agency (2020-01911 05).

**Next-generation sequencing**

Genomic DNA was extracted from whole blood. For the 1,533 patients included, the whole exome \((n=1035)\) or whole genome \((n=498)\) was sequenced at several sequencing centers, including the Genomics Core Facility of the Imagine Institute (Paris, France), the Yale Center for Genome Analysis (USA), the New-York Genome Center (NY, USA), and the American Genome Center (TAGC, USUHS, Bethesda, USA), and the Genomics Division-ITER of the Canarian Health System sequencing hub (Canary Islands, Spain).

For WES, libraries were generated with the Twist Biotechnology kit (Twist Human Core Exome Kit), the xGen Exome Research Panel from Integrated DNA Technologies (IDT xGen), the Agilent SureSelect V7 kit or the SeqCap EZ MedExome kit from Roche, and the Nextera Flex for Enrichment-Exome kit (Illumina). Massively parallel sequencing was performed on a HiSeq4000 or NovaSeq6000 system (Illumina). For WES analysis performed at CNAG Barcelona, Spain, capture was performed with the SeqCap EZ Human Exome Kit v3.0 (Roche Nimblegen, USA) and 100-bp paired-end read sequences were obtained on a HiSeq 2000-4000 platform (Illumina, Inc. USA). For the OSR Italian cohort, WES was performed with the Agilent SureSelect V7 kit on a NovaSeq6000 system (Illumina).

For WGS on patients of the Italian cohort (TAGC), genomic DNA samples were dispensed into the wells of a Covaris 96 microTUBE plate \((1,000 \text{ ng per well})\) and sheared with the Covaris LE220 Focused-ultrasonicator, at settings targeting a peak size of 410 bp (t:78; Duty:18; PIP:450; 200 cycles). Sequencing libraries were generated from fragmented DNA with the Illumina TruSeq DNA PCR-Free HT Library Preparation Kit, with minor modifications for automation (Hamilton STAR Liquid Handling System), with IDT for Illumina TruSeq DNA UD Index (96 indices, 96 samples) adapters. Library size distribution was assessed and the absence of free adapters or adapter dimers was checked by automated capillary gel electrophoresis (Advanced Analytical Fragment Analyzer). Library concentration was determined by qPCR with the KAPA qPCR Quantification Kit (Roche Light Cycler 480 Instrument II). Sequencing libraries were normalized and combined as 24-plex pools and quantified as above, before dilution to 2.9 nM and sequencing on an Illumina NovaSeq 6000 with the S4 Reagent Kit (300 cycles) and 151+8+8+151 cycle run parameters. Primary sequencing data were demultiplexed with the Illumina HAS2.2 pipeline and sample-level quality control was performed for base quality, coverage, duplicates and contamination (FREEMIX < 0.05 by VerifyBamID). For patients enrolled in the Swedish COVID cohort, sequencing was performed at the Clinical Genomics Stockholm unit of the SciLifeLab (Stockholm, Sweden).

We used the Genome Analysis Software Kit (GATK) (version 3.4-46 or 4) best-practice pipeline to analyze our WES data (69). We aligned the reads obtained with the human reference genome (hg19), using the maximum exact matches algorithm in the Burrows-Wheeler Aligner (BWA) (70). PCR duplicates were removed with Picard tools (picard.sourceforge.net). The GATK base quality score recalibrator was applied to correct sequencing artifacts. Genotyping was performed with GATK GenotypeGVCFs in the interval intersecting all the capture kits ± 50 bp. Sample genotypes with a coverage < 8X, a genotype quality (GQ) < 20, or a ratio of reads for the less covered allele (reference or variant allele) over the total number of reads covering the position (minor read ratio, MRR) < 20% were filtered out. We filtered out variant sites (i) with a call rate <50% in gnomAD genomes and exomes, (ii) a non-PASS filter in the gnomAD database, (iii) falling in low-complexity or decoy regions, (iv) that were multi-allelic with more than four alleles, (v) with more than 20% missing genotypes in our cohort, and (vi) spanning more than 20 nucleotides. Variant effects were predicted with the Ensembl Variant Effect Predictor (VEP) (71) and the Ensembl GRCh37.75 reference database, retaining the most deleterious annotation obtained from Ensembl canonical transcripts overlapping with RefSeq transcripts.

**Statistical analysis**

We performed an enrichment analysis focusing on X chromosome genes on our cohort of 1,202 male patients with life-threatening COVID-19 pneumonia without known inborn errors of TLR3- and IRF7-dependent type I IFN immunity (8) and without neutralizing auto-Abs against type I IFNs (9), and 331 male individuals with asymptomatic or paucisymptomatic infection (Table S1). We considered variants that were predicted to be loss-of-function or missense, with a MAF below 0.0001 (gnomAD v2.1.1). We compared the proportion of patients and controls carrying at least one non-synonymous variant at almost every single acceptor or donor site in every gene (Table S1). We considered that the approach of Firth’s regression was best practice for logistic regression and that the approach using sample size and the number of non-synonymous variant sites (i) with a call rate <50% in gnomAD genomes and exomes, (ii) a non-PASS filter in the gnomAD database, (iii) falling in low-complexity or decoy regions, (iv) that were multi-allelic with more than four alleles, (v) with more than 20% missing genotypes in our cohort, and (vi) spanning more than 20 nucleotides. Variant effects were predicted with the Ensembl Variant Effect Predictor (VEP) (71) and the Ensembl GRCh37.75 reference database, retaining the most deleterious annotation obtained from Ensembl canonical transcripts overlapping with RefSeq transcripts.
the cohorts by including the first five principal components of the PCA in the Firth’s logistic regression model. Analyses were also adjusted for age in years. We checked that our adjusted burden test was well-calibrated by also performing an analysis of enrichment in rare (MAF < 0.0001) synonymous variants. PCA was performed with Plink v1.9 software on whole-exome and whole-genome sequencing data, with the 1000 Genomes (1kG) Project phase 3 public database as a reference, using 18,917 exonic variants with a minor allele frequency > 0.01 and a call rate > 0.99.

**Cell culture**

EBV-B cell lines derived from the patients were grown in complete RPMI 1640 (Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (FBS). HEK293T cells, derived from the human embryonic kidney 293 cell line, which expresses a mutant version of the SV40 large T antigen, were grown in complete DMEM (Life Technologies) supplemented with 10% FBS. Cells were incubated at 37°C in the presence of 5% CO₂.

**Expression vectors and transfection experiments**

All the TLR7 variants in our analysis were generated by site-directed mutagenesis (Data file S4). The WT or variant alleles were re-introduced into a Myc-DDK-pCMV6 vector (Origene). HEK293T cells, which have no endogenous TLR7 or TLR8 expression, were transfected with the Myc-DDK-pCMV6 vector, empty or containing the WT or a variant allele, in the presence of X-tremeGENE 9 DNA Transfection Reagent (Sigma-Aldrich), according to the manufacturer’s instructions.

**Western blotting**

For whole-cell extracts, the cells were lysed by incubation in the following buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP40), supplemented with a mixture of protease inhibitors (Sigma-Aldrich), for 30 min at 4°C. The lysates were then centrifuged at 21,000 × g for 20 min at 4°C. The supernatants were processed directly for Western blotting. Western blotting was performed on 10 μg of total extract from transfected HEK293T cells, with monoclonal antibodies specific for the leucine-rich repeats to the N terminus within the human TLR7 protein (Cell Signaling Technology; clone, D7), or for amino-acid 1,000 to the C terminus with the human TLR7 protein (Abcam; clone, EPR2088(2)).

**Luciferase reporter assay**

HEK293T cells, which have no endogenous TLR7 expression, were transfected with the pCMV6 vector bearing wild-type or variant TLR7 (50 ng), the reporter construct pGL4.32 (100 ng), and an expression vector for Renilla luciferase (10 ng), with the X-tremeGENE 9 DNA Transfection Reagent kit (Sigma-Aldrich). The pGL4.32 [luc2P/NF-κB-RE/Hygro] (Promega) reporter vector contains five copies of the NF-κB-responsive element (NF-κB-RE) linked to the luciferase reporter gene luc2P. After 24 hours, the transfected cells were left unstimulated or were stimulated with 1 μg/mL R848 (Resquimod), for activation via TLR7/8 (Invivogen), or 5 μg/mL R837 (Imiquimod) (Invivogen), or 5 μg/mL CL264 (Invivogen), human TLR7-specific agonists, for 24 hours. Relative luciferase activity was then determined by normalizing the values against the firefly:Renilla luciferase signal ratio.

**RNA extraction and reverse transcription-quantitative PCR (RT-qPCR)**

Total RNA was extracted with the RNeasy Mini Kit (Qiagen), according to the manufacturer’s instructions. Reverse transcription was performed on 1 μg of RNA with random primers and the SuperScript III reverse transcriptase (Invitrogen), according to the manufacturer’s protocol. Quantitative PCR was then performed with the TaqMan Fast Universal PCR Master Mix (2X) and the FAM-MGB TaqMan TNF exons 1-2 (Hs99999943_m1) probes. The VIC-TAMRA probe for GUSB (Applied Biosystems, Cat: 4310888E) was used as an endogenous control. Real-time PCR amplification was monitored with the 7500 Fast Real-Time PCR System (Applied Biosystems). Relative expression levels were determined according to the ΔCt method.

**ELISA analysis of TNF production in EBV-B cells**

ELISA was performed as previously described (50). We suspended 1x10⁵ EBV-B cells per well in RPMI 1640 supplemented with 10% FBS. The cells were activated by incubation with 1 μg/mL R848, and 5 μg/mL imiquimod for 24 hours. The supernatants were harvested after 24 hours of activation. ELISA determinations of TNF in cell culture supernatants were performed with a kit (Thermo Fisher Scientific), according to the manufacturer’s instructions.

**Stable transduction**

The WT coding sequence of TLR7 was inserted into pTRIP-CMV-puro-2A. For lentivirus production, HEK293T cells were transfected with 1.6 μg pTRIP-CMV-puro-2A-TLR7-WT (or Mutant: K684*), 0.2 μg pCMV- VSV-G (Addgene), 0.2 μg pHXB2 (NIH-AIDS Reagent 22 Program) and 1 μg psPAX2 (Addgene), with X-treme gene 9 (Roche), according to the manufacturer’s instructions. Supernatants were harvested after 24 hours and 8 μg/mL protamine sulfate was added. The lentiviral suspension obtained was used to transduce 2x10⁵ EBV-B cells by spinoculation at 1,200 x g for 2 hours. The transduced cells were selected by incubation on medium containing 1 μg/mL puromycin for two days. The cells were then selected by incubation for a further two days on medium containing 2 μg/mL puromycin. During viral transduction, the cells were cultured with 5 μM IRAK4 inhibitor (PF06650833) (Bio-technne) to prevent cell death due to the overproduction of TLR7. Selected transduced cells were then stimulated with 1 μg/mL R848 or 5 μg/mL imiquimod for 24 hours without IRAK4 inhibitor. The supernatants were harvested after 24 hours of activation. ELISA determinations of TNF in cell culture supernatants were performed with a kit (Thermo Fisher Scientific).
VirScan analysis
Patient serum was analyzed by VirScan in two independent experiments as previously described (78). Briefly, an oligonucleotide library encoding 56 amino acid peptides tiling across the genomes of 206 viral species was synthesized on a releasable DNA microarray and cloned into T7 phage. Patient serum containing 2 μg of IgG was added to the phage library, and immunoprecipitation was performed with Protein A and G beads. Enriched peptides were identified by PCR and Illumina sequencing of the peptide cassette from the immunoprecipitated phage.

Deep immunophenotyping by mass cytometry (CyTOF)
CyTOF was performed on whole blood with the Maxpar Direct Immune Profiling Assay (Fluidigm), according to the manufacturer's instructions. Cells were frozen at -80°C after overnight staining to eliminate dead cells, and acquisition was performed on a Helios machine (Fluidigm). All the samples were processed within 24 hours of sampling. Data analysis was performed with OMIQ software. Antibody information is listed in supplemental material (Data file S5).

PBMC enrichment using MACS system
Blood were collected from two healthy individuals and separated by the concentration gradient method with Ficoll*-Paque Plus (Cytiva). After isolation of PBMCs, leukocyte subset (T cell, B cell, monocyte, pDC, and mDC) were purified by negative selection using MACS beads system (Miltenyi Biotec). Cells were plated into a U-bottomed 96-well plate at a density of 2 × 10^6 cells/well for T cells, B cells, monocytes, pDCs, or mDCs in 200 μL/well RPMI-1640 with GlutaMAX supplemented with 10% FBS or 10 × 10^6 cells/well for whole blood and PBMCs. Cells were left unstimulated or stimulated with 1 μg/mL CL264, 100ng/ml TL8-506 (Invivogen), 1 μM CpG-c (Invivogen), or 12.5ng/ml PMA and 0.125 μM ionomycin for 24 hours. The supernatants were harvested after 24 hours of activation. Cytokines production was determined by ELISA (IFN-α - PBL Assay Science, IFN-β - PBL Assay Science, IFN-γ (IL-29) - Invitrogen, IFN-ω - Invitrogen or IL-8 - R&D SYSTEMS); according to the manufacturer's instructions.

Analysis for TLR7 and TLR8 expression pattern in peripheral blood mononuclear cells (PBMCs) by flow cytometry
Freshly thawed PBMCs from healthy donors were dispensed into a V-bottomed 96-well plate at a density of 1 × 10^6 cells/well, in 200 μL PBS/well. In brief, cells were stained by incubation with the LIVE/DEAD fixable blue dead-cell staining kit (Thermo Fisher Scientific, 1:800) and FcR blocking reagent (Miltenyi Biotec, 1:25) on ice for 15 min. For surface staining, cells were incubated with anti-γδ TCR-BUV611 (BD Biosciences, 1:50), anti-CD183-BV750 (BD Biosciences, 1:20), and anti-CD194-BUV615 (BD Biosciences, 1:20) antibodies on ice for 30 min in 0.1% BSA and 0.01% sodium azide in PBS. They were then incubated with anti-CD141-BS515 (BD Biosciences, 1:40), anti-CD57-FITC (Biolegend, 1:83), anti-TCR Vδ2-PerCP (Biolegend, 1:166), anti-TCR Vγ7.2-PerCP/Cyanine5.5 (Biolegend, 1:40), anti-TCR Vα1-PerCP-Vio700 (Miltenyi Biotec, 1:100), anti-CD14-Spark Blue 550 (Biolegend, 1:40), anti-CD1c-Alexa Fluor 647 (Biolegend, 1:50), anti-CD38-APC/Fire 810 (Biolegend, 1:30), anti-CD27-APC-H7 (BD Biosciences, 1:50), anti-CD127-APC-R700 (BD Biosciences, 1:50), anti-CD19-Spark NIR 685 (Biolegend, 1:83), anti-CD45RA-BUV395 (BD Biosciences, 1:83), anti-CD16-BUV496 (BD Biosciences, 1:166), anti-CD11b-BUV563 (BD Biosciences, 1:100), anti-CD56-BUV737 (BD Biosciences, 1:83), anti-CD8-BUV805 (BD Biosciences, 1:83), anti-hMR1-BV421 (NIH tetramer facility, 1:100), anti-CD11c-BV480 (BD Biosciences, 1:40), anti-CD45-BV510 (Biolegend, 1:83), anti-CD33-BV570 (Biolegend, 1:83), anti-INKT-BV605 (Biolegend, 1:25), anti-CD161-BV650 (BD Biosciences, 1:25), anti-CCR6-BV711 (Biolegend, 1:83), anti-CCR7- BV785 (Biolegend, 1:40), anti-CD3-Pacific Blue (Biolegend, 1:83), anti-CD20-Pacific Orange (Life Technologies, 1:50), anti-CD123-Super Bright 436 (Innvetrogen, 1:40), anti-CD24-PE-Alexa Fluor 610 (Life Technologies, 1:25), anti-CD29-PE-Alexa Fluor 810 (Biolegend, 1:30), anti-CD27-APC-H7 (BD Biosciences, 1:50), anti-CD38-APC-Fire 810 (Biolegend, 1:50), and anti-CD4-CF97(TM)-YG584 (Cytek, 1:83) antibodies on ice for at least 30 min. The cells were then washed and stained by incubation with streptavidin-PE/Cy5 (Biolegend, 1:3000) on ice for 30 min. The cells were then fixed and permeabilized for intracellular staining with anti-TLR7-PE (Invitrogen) and anti-TLR8-APC (Biolegend) antibodies, with the eBioscience Foxp3/Transcription Factor Staining Buffer Set (Invitrogen), according to the manufacturer's instructions. The cells were then washed and acquired with a five-laser Cytek Aurora (Cytek) flow cytometer. Antibody clone information is added in a supplemental material (Data file S6).

pDC activation
Freshly purified pDCs were cultured in 96-well plates at a concentration of 5 × 10^5 cells per mL in the presence of medium alone (RPMI 1640 Medium with GlutaMAX, 10% FBS, 1% MEM NEAA, 1% sodium pyruvate, and 1% penicillin/streptomycin), CL264 (Invivogen, 1 μg/mL), or the SARS-CoV-2 primary strain 220_95 (45) at a multiplicity of infection (MOI) of 1. After 24 hours of culture, the pDC supernatant was collected for cytokine quantification, and the PDCs were collected for diversification assessment by flow cytometry. In some experiments, RNA was purified from the pDCs were analyzed by RNA-seq (see below).

Flow cytometry analysis for human pDCs
For assessments of pDC diversification, cells were stained

First release: 19 August 2021 immunology.sciencemag.org (Page numbers not final at time of first release) 10
with Zombie Violet fixable viability dye (Biolegend), BV711 anti-CD123 (Biolegend, clone 6H6), PE anti-CD80 (BD, clone L307.4), and PerCP-efluor 710 anti-PD-L1 (eBioscience, clone M1H1) antibodies. Data were acquired with an LSR Fortessa (BD Biosciences) flow cytometer and analyzed with FlowJo software (Tree Star). Flow cytometry analyses were performed at the flow cytometry core facility of IRSL (Paris, France).

**RNA-Sequencing**

We collected cells from five individuals in two families: one patient (P8) and two healthy controls (H.II.2, H.II.3) from family M. These cells were stimulated with three conditions: non-stimulation, SARS CoV-2, and CpG-c. Total RNA was extracted from pDC cells with RNeasy Micro kits (QIAGEN). RNA-Seq libraries were prepared with the Illumina SMART-Seq v4 PLUS Kit (TaKaRa) and sequenced on the Illumina NextSeq 4000 platform with single-end 75 bp configuration. The RNA-Seq fastq raw data were inspected with multiqc v1.10 (72) to ensure the high quality of data. The sequencing reads were mapped onto the human reference genome GRCh38 with STAR aligner v2.7 (73), and the mapped reads were then quantified to determine the gene-level read counts with featureCounts V2.0.2 (74) and GENCODE human gene annotation GRCh38.p13 (75). The gene-level read counts were normalized and log2-transformed by DESeq2 (76), to obtain the gene expression profile of all samples for differential expression analysis. The differential gene expression was analyzed by applying TMM normalization and gene-wise generalized linear model regression with edgeR (77). The genes displaying significant differential expression were selected on the basis of |log2FoldChange| ≥ 2 and FDR ≤ 0.05. The gene-level read counts of IFN genes were transformed to RPKM (Reads Per Kilobase of transcript, per Million mapped reads) by our own scripts, considered how biological sex impacts immune responses and COVID-19 outcomes. Nature Rev. Immunol. 20, 442–447 (2020). doi:10.1038/s41577-020-0348-8 Medline

**Determination of secreted inflammatory cytokines**

We measured the production, by pDCs, of IFN-α, IL-8, IL-6, and IP-10, by determining the levels of these cytokines in culture supernatants with the BD cytometric bead array (CBA), according to the manufacturer’s protocol, with a limit of detection of 20 pg/mL. Acquisitions were performed on an LSR Fortessa (BD Biosciences) flow cytometer, and cytokine concentrations were determined with FCAP Array Software (BD Biosciences).

**SUPPLEMENTARY MATERIALS**

immunology.sciencemag.org/cgi/content/full/5/s2/eabl4348/DC1

- Figure S1: Ethnicity information and TL7 allele activity
- Figure S2: Allele activity for the TL7R variants found in our cohort
- Figure S3: VirScan analysis of specific anti-viral antibodies detected in patient sera
- Figure S4: Levels of TNF induction in EBV-B cells derived from two patients with XR TL7R deficiency
- Figure S5: Analysis of peripheral blood mononuclear cells from TL7-deficient men
- Figure S6: Functional analysis in pDCs infected with SARS-CoV-2
- Table S1: Characteristics of the cohort of patients with life-threatening COVID-19 pneumonia and the control cohort of asymptomatic or paucisymptomatic individuals
- Table S2: Statistical analysis of non-synonymous rare variants of TL7R and TL8R in our cohorts
- Table S3: Summary of TL7R variants
- Data file S1: Selection of genes on chromosome X with 5 or more hemizygous carriers (Excel file).
- Data file S2: TL7R variant activity reported in this study, in previous studies and in gnomAD (Excel file).
- Data file S3: TL7-deficient patients with severe/critical COVID-19 in our cohort (clinical information, laboratory findings, and immunological findings) (Excel file).
- Data file S4: Primer sequences for mutagenesis (Excel file).
- Data file S5: Antibody information for CyTOF (Excel file).
- Data file S6: Gating strategy and antibody clone information for 40 color immunophenotyping (Excel file).
- Data file S7: Raw data files (Excel file).

**REFERENCES AND NOTES**


We thank the patients and families; the members the A.K.-K., A.Am., A.C., A.G., A.-L.N., Be.Bo., E.J.,...
Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. 41Universidad de Antioquia, Group of Primary Immunodeficiencies, Antioquia UdeA, Medellin, Colombia. 42The Genetics Institute, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 43Pediatric Nephrology, Rheumatology, Dermatology, HFME, Hospices Civils de Lyon, National Reference Centre RAISE, and INSERM U1111, Université de Lyon, Lyon, France. 44Department of Pediatrics, British Columbia Children’s Hospital. The University of British Columbia, Vancouver, BC, Canada 45Ichsan School of Medicine at Mount Sinai, New York, NY, USA. 46Helix, San Mateo, CA, USA. 47Shupyk National Medical Academy for Postgraduate Education, Kiev, Ukraine. 48Clinical Immunology Unit, Department of Pediatric Infectious Disease, CHU Ibn Rushd and LIOIA, Laboratoire d’Immunologie Clinique, Inflammation et Allergie, Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco. 49SciLifeLab, Department Of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden. 50Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden. 51Stanford University, Stanford, CA, USA. 52Division of Immunology, Allergy, and Rheumatology, Department of Pediatrics and the Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA, USA. 53Clinical Genomics, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy. 54Department of Pediatrics and Children’s Healthcare of Atlanta, Emory University, Atlanta, GA, USA. 55Murdoch Children’s Research Institute and Department of Pediatrics, University of Melbourne, Australia 56Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. 57de Duve Institute and Ludwig Cancer Research, Brussels, Belgium. 58Washington University School of Medicine, St. Louis, MO, USA. 59Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. 60Bai Jerbai Wadia Hospital for Children, Mumbai, India. 61School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA. 62Genetics Unit, Military Hospital Mohamed V, Rabat, Morocco. 63Instituto Nacional de Pediatría (National Institute of Pediatrics), Mexico City, Mexico. 64School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. 65Genomics Division, Instituto Tecnológico y de Energías Renovables (ITER), Santa Cruz de Tenerife, Spain; Research Unit, Hospital Universitario N.S. de Canícula, Santa Cruz de Tenerife, Spain; Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, Santa Cruz de Tenerife, Spain; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain. 66Pulmonology Department, Cliniques Universitaires Saint-Luc; Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium. 67Feinstein Institute for Medical Research, Northwell Health USA, Manhasset, NY, USA. 68Department of Pediatric Immunology and Pulmonology, Centre for Primary Immunodeficiency Ghent (CPIG), PID Research Laboratory, Jeffrey Model Diagnosis and Research Centre, Ghent University Hospital, Ghent, Belgium. 69The Genetics Institute Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 70Sharjah Institute for Medical Research, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. 71Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden. 72Department for Systems Biology, Seattle, WA, USA. 73Department of Pediatrics, Division of Allergy Immunology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 74Departments of Pediatrics, Immunology and Microbiology, University of Colorado, School of Medicine, Aurora, Colorado, USA 75Department of Medicine, Haukeland University Hospital, Bergen, Norway. 76Department of Community Pediatrics, Perinatal and Maternal Medicine, Tokyo Medical and Dental University (TMDU) 77Institute for Personalized Medicine, Ichsan School of Medicine at Mount Sinai, New York, NY, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 78Laboratory of Neurogenetics of Language and Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA. 79Bioinformatics and Applied Genomics Unit, Hellenic Pasteur Institute, Athens, Greece 80Molecular Pathology, Department of Biomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu Estonia. 81Chang Gung University, Taoyuan County, Taiwan. 82Department of Pediatrics & Adolescent Medicine, The University of Hong Kong, Hong Kong, China. 83Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. 84Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA. 85Columbia University Zuckerman Institute, New York, NY. 86Department of Clinical Immunology and Infectious Diseases, National Research Institute of Tuberculosis and Lung Diseases, The Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 87Primary Immunodeficiency Clinical Unit and Laboratory, Department of Dermatology, Venerology and Dermatooncology, Semmelweis University, Budapest, Hungary. 88Department of Pediatrics, University Hospitals Leuven; KU Leuven, Department of Microbiology, Immunology and Transplantation; Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium. 89Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, USA. 90University Clinic for Children's Diseases, Department of Pediatric Immunology, Medical Faculty, University “St.Cyril and Methodi” Skopje, North Macedonia. 91Department of Biomedicine, Aarhus University, Aarhus, Denmark 92Tokyo Medical & Dental University Hospital, Tokyo, Japan. 93A*STAR Infectious Disease Labs, Agency for Science, Technology and Research, Singapore; Lee Kong Chian School of Medicine, Nanyang Technology University, Singapore. 94National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 95Laboratory of Medical Genetics, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy, 96Department of Biomedicine and Prevention, Tor Vergata University of Rome, Rome, Italy. 97Comparative Immunology Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland. 98Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. 99Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey. 100Laboratory of Immunogenetics of Human Diseases, Immune Institute Group, iDiPAZ Institute for Health Research, La Paz Hospital, Madrid, Spain. 101IBB-CSIC, IDIBAPS, Barcelona, Spain. 102Facultades Pequeno Príncipe, Instituto de Pesquisa Pele Pequeno Principe, Curitiba, Brazil. 103Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain; Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain; Center for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain. 104Human Evolutionary Genetics Unit, CNRS U2000, Institut Pasteur, Paris, France; Human Genomics and Evolution, College de France, Paris, France. 105University Hospital St. Marina, Varna, Bulgaria. 106Department of Immunology, University Hospital of Gran Canaria Dr. Negrín, Canarian Health System, Las Palmas de Gran Canaria, Spain; Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain 107Department of Pediatric Infectious Diseases and Virology, Imperial College London, London, UK; Centre for Pediatrics and Child Health, Faculty of Medicine, Imperial College London, London, UK. 108Department of Immunology, Second Faculty of Medicine Charles University, V Uval, University Hospital in Motol, Prague, Czech Republic. 109Adult Immunodeficiency Unit, Infectious Diseases, Immunology Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Rare Diseases Center and Pediatric Research Center, Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland 110Saeed Pathobiology and Genetics Lab, Tehran, Iran; Department of Microbiology and Immunology, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium. 111Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia. 112Central European Institute of Technology & Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 113Department of Pharmacology & Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. 114Pediatric Infectious Diseases and Immunodeficiencies Unit, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain. 115St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands 116Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria. 117Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia. 118AJ Jallal Children’s Hospital,
A

TLR7

-\log_{10}(p)

X chromosome position (Mbp)

B

TLR7 (N-ter Ab)

TLR7 (C-ter Ab)

GAPDH

C

NF-κB activity (% of WT)

D

NF-κB activity (% of WT)

E

NF-κB activity (% of WT)

Critical COVID (this study)

Severe COVID (this study)

Critical COVID (reported)

gnomAD (v.2.1.1)
Fig. 1. Enrichment in rare TLR7 deleterious alleles among men with critical COVID-19 pneumonia. (A) Manhattan plot showing the results of the variant enrichment test for the 190 genes of the X chromosome with at least 5 patients carrying non-synonymous variants. The gray line indicates the corresponding Bonferroni-corrected significance threshold. (B) Western blot of extracts from non-transfected HEK293T cells (mock), HEK293T cells transfected with pCMV6 empty vector (EV), the wild-type (WT) TLR7 allele, or one of the TLR7 variant alleles of interest. All extracts were probed with monoclonal antibodies specific for the leucine-rich repeats to the N terminus (N-ter) or amino-acid 1,000 to the C terminus (C-ter) within the human TLR7 protein. (C) Western blot of extracts from non-transfected HEK293T cells (mock), HEK293T cells transfected with pCMV6 empty vector (EV), the wild-type (WT) TLR7 allele, or one of the TLR7 variant alleles of interest. All extracts were probed with monoclonal antibodies specific for the leucine-rich repeats to the N terminus (N-ter) or amino-acid 1,000 to the C terminus (C-ter) within the human TLR7 protein. (D) Luciferase assay on HEK293T cells transfected with the pGL4.32 luciferase reporter construct and an expression vector for Renilla luciferase together with no vector (mock), EV, WT, or TLR7 variants: (C) 21 variants found in our cohort and eight previously reported variants, (D) 109 variants found in male individuals from the gnomAD database. After 24 hours, transfected cells were left untreated or were treated by incubation with 1 μg/mL R848 for 24 hours. These data were established from two independent experiments. The y-axis represents NF-κB transcriptional activity as a percentage of the WT. The x-axis indicates the alleles used for transfection. (E) Luciferase assay on HEK293T cells transfected with the pGL4.32 luciferase reporter construct and an expression vector for Renilla luciferase together with no vector (mock), EV, WT, or TLR7 variants: (C) 21 variants found in our cohort and eight previously reported variants, (D) 109 variants found in male individuals from the gnomAD database. After 24 hours, transfected cells were left untreated or were treated by incubation with 1 μg/mL R848 for 24 hours. These data were established from two independent experiments. The y-axis represents NF-κB transcriptional activity as a percentage of the WT. The x-axis indicates the alleles used for transfection. (E) Luciferase assay on HEK293T cells transfected with the pGL4.32 luciferase reporter construct and an expression vector for Renilla luciferase together with no vector (mock), EV, WT, or TLR7 variants: (C) 21 variants found in our cohort and eight previously reported variants, (D) 109 variants found in male individuals from the gnomAD database. After 24 hours, transfected cells were left untreated or were treated by incubation with 1 μg/mL R848 for 24 hours. These data were established from two independent experiments. The y-axis represents NF-κB transcriptional activity as a percentage of the WT. The x-axis indicates the alleles used for transfection. (E) Luciferase assay on HEK293T cells transfected with the pGL4.32 luciferase reporter construct and an expression vector for Renilla luciferase together with no vector (mock), EV, WT, or TLR7 variants: (C) 21 variants found in our cohort and eight previously reported variants, (D) 109 variants found in male individuals from the gnomAD database. After 24 hours, transfected cells were left untreated or were treated by incubation with 1 μg/mL R848 for 24 hours. These data were established from two independent experiments. The y-axis represents NF-κB transcriptional activity as a percentage of the WT. The x-axis indicates the alleles used for transfection. (E) Luciferase assay on HEK293T cells transfected with the pGL4.32 luciferase reporter construct and an expression vector for Renilla luciferase together with no vector (mock), EV, WT, or TLR7 variants: (C) 21 variants found in our cohort and eight previously reported variants, (D) 109 variants found in male individuals from the gnomAD database. After 24 hours, transfected cells were left untreated or were treated by incubation with 1 μg/mL R848 for 24 hours. These data were established from two independent experiments. The y-axis represents NF-κB transcriptional activity as a percentage of the WT. The x-axis indicates the alleles used for transfection.
Fig. 2. X-linked recessive TLR7 deficiency in 16 kindreds. (A) Pedigrees of the 16 kindreds containing 17 patients with life-threatening COVID-19 pneumonia (P1-17) bearing deleterious TLR7 alleles. The mutations are indicated above each pedigree. Solid black symbols indicate patients with critical COVID-19, and solid dark gray symbols indicate severe cases and solid light gray symbols indicate mild/moderate cases. The genotype is indicated under each symbol, with M corresponding to the mutation found in each kindred. ‘+’ and ‘-’ indicate the presence and absence, respectively, of antibodies against SARS-CoV-2 in the serum of the individual. Asymptomatic or paucisymptomatic family members hemizygous for the mutation are indicated by bold vertical lines. (B) Pedigree of one kindred containing two patients with severe COVID-19. (C) Schematic representation of TLR7. The upper part represents the genomic organization of the TLR7 locus, with rectangles for the various exons of the gene, and exon numbers indicated within the rectangle. The bottom part shows the primary structure of TLR7. The N-terminal portion and the leucine-rich repeat containing 26 leucine residues are located in the lumen of the endosome, and TM indicates the transmembrane domain. The Toll/interleukin-1 (IL-1) receptor (TIR) domain is cytoplasmic. The deleterious mutations reported in this study are indicated. (D) TLR7 expression in unstimulated EBV-B cells from two patients with XR TLR7 deficiency (P12 and P14), the fathers of P12 and P14, and the mother of P12, and three healthy donors (Control 1 to 3), determined by Western blotting with detection with a specific TLR7 antibody. (E) TNF production by XR TLR7-deficient EBV-B cells from two independent experiments. Cells were either left untreated or were stimulated with 5 μg/mL imiquimod (gray), or 25 ng/mL PMA and 0.25 μM ionomycin (black) for 24 hours and TNF production were measured by ELISA. (F) TNF production in XR TLR7-deficient EBV-B cells re-expressing WT TLR7 from three independent experiments. EBV-B cells from a control, P12, P14, or an UNC-93B-deficient patient, cultured in the presence of IRAK4 inhibitor (PF06650833-5 μM) were transduced with lentiviral particles that were empty or contained the WT TLR7 or mutant TLR7 cDNA. The cells were incubated for 24 hours without IRAK4 inhibitor and were then left untreated or were stimulated with 5 μg/mL imiquimod (light gray), 1 μg/mL R848 (dark gray), or 25 ng/mL PMA and 0.25 μM ionomycin (black) for 24 hours, and TNF production were measured by ELISA. Statistical tests were performed using one-way ANOVA with Dunnett’s post hoc test (*: P < 0.05, ns: not significant).
Fig. 3. Type I IFN responses to TLR7 agonist in TLR7-deficient pDCs and leukocytes. (A) Frequencies of five leukocyte subsets in whole blood, determined by CyTOF. Healthy donors (black rectangles), relatives not carrying deleterious TLR7 alleles (blue rectangles) and hemizygous TLR7 variant carriers (red rectangles) are depicted. (B) TLR7 and TLR8 expression in different leukocyte subsets, determined by flow cytometry for the healthy control (C1). The result for another healthy control (C2) is shown in Figure S5C. Gating strategy for the classification in each cell subset is shown in Data file S6. (C) IFN-α production in purified leukocyte subsets from two healthy donors (blue or yellow dot) with and without stimulation with various TLR7, 8, or 9 agonists (1 μg/mL CL264, 100 ng/mL TL8-506, 1 μg/mL R848, or 2 μM CpG-c) for 24 hours. The y-axis shows IFN-α production on a logarithmic scale. The red bar corresponds to pDCs. (D) pDCs isolated from healthy donors and TLR7-deficient patients (P8, P14) were either left untreated (medium) or were stimulated with CL264 or CpG-c, and the production of IFN-α2 and IL-6 was assessed with CBAs on the supernatant. (E) Dotplot showing pDC diversification into subsets S1, S2, and S3 from magnetically sorted blood. pDCs from a TLR7-deficient patient (P14) and a healthy relative (M.I.1) were cultured for 24 hours with medium alone or with 1 μg/mL CL264 or 2 μM CpG-c. Statistical tests were performed using unpaired two-sample t test (*: P < 0.05).
Fig. 4. Type I IFN responses to SARS-CoV-2 infection in TLR7-deficient pDCs. (A) pDCs isolated from healthy relatives and TLR7-deficient patients (P8, P14) were either left untreated or were infected with SARS-CoV-2 for 24 hours. RNA profiles were then determined by RNA-seq. Genes with expression >2.0-fold higher or lower in controls after stimulation or infection are plotted as the fold-change in expression. (B) Induction of the type I and III IFN genes from (A) infected with SARS-CoV-2 for 24 hours (top) or stimulated with CpG-c (bottom). (C) pDCs isolated from healthy relatives and TLR7-deficient patients (P8, P14) were either left untreated or were infected with SARS-CoV-2 for 24 hours and the production of IFN-α2, IP-10, IL-6 and IL-8 was measured with CBAs on the supernatant. Statistical tests were performed using unpaired two-sample t test (*: P < 0.05, ****: P < 0.0001, ns: not significant).
Table 1. X-linked TLR7 deleterious variants in 16 unrelated male patients with life-threatening COVID-19 pneumonia.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Genotype</th>
<th>Age [years]</th>
<th>Ethnicity</th>
<th>Ancestry/residence</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>L134P/Y</td>
<td>45</td>
<td>Admixed American</td>
<td>Paraguay/Spain</td>
<td>Survived</td>
</tr>
<tr>
<td>P2</td>
<td>N158Tfs11*/Y</td>
<td>60</td>
<td>European</td>
<td>France</td>
<td>Deceased</td>
</tr>
<tr>
<td>P3</td>
<td>L227fs*/Y</td>
<td>34</td>
<td>Middle East</td>
<td>Iran</td>
<td>Survived</td>
</tr>
<tr>
<td>P4</td>
<td>D244Y/Y</td>
<td>13</td>
<td>Middle East</td>
<td>Turkey</td>
<td>Survived</td>
</tr>
<tr>
<td>P5</td>
<td>F310L/Y</td>
<td>39</td>
<td>Middle East</td>
<td>Iran</td>
<td>Survived</td>
</tr>
<tr>
<td>P6</td>
<td>L372M</td>
<td>7</td>
<td>Caucasian (Central Asia based on GME Variome)</td>
<td>Iran</td>
<td>Survived</td>
</tr>
<tr>
<td>P7</td>
<td>I505T/Y</td>
<td>55</td>
<td>European</td>
<td>Italy</td>
<td>Survived</td>
</tr>
<tr>
<td>P8</td>
<td>H630Y/Y</td>
<td>50</td>
<td>European</td>
<td>Spain</td>
<td>Survived</td>
</tr>
<tr>
<td>P9</td>
<td>I657T/Y</td>
<td>18</td>
<td>European</td>
<td>Italy</td>
<td>Survived</td>
</tr>
<tr>
<td>P10</td>
<td>F670Lfs*8</td>
<td>31</td>
<td>European</td>
<td>Sweden</td>
<td>Survived</td>
</tr>
<tr>
<td>P11*</td>
<td>F670Lfs*8</td>
<td>29</td>
<td>European</td>
<td>Sweden</td>
<td>Survived</td>
</tr>
<tr>
<td>P12</td>
<td>K684*/Y</td>
<td>30</td>
<td>European</td>
<td>Spain</td>
<td>Survived</td>
</tr>
<tr>
<td>P13</td>
<td>P715S/Y</td>
<td>40</td>
<td>Latino</td>
<td>Colombia</td>
<td>Survived</td>
</tr>
<tr>
<td>P14</td>
<td>H781L/Y</td>
<td>13</td>
<td>Middle East</td>
<td>Russia/France</td>
<td>Survived</td>
</tr>
<tr>
<td>P15</td>
<td>L988S/Y</td>
<td>26</td>
<td>Middle East</td>
<td>Iran</td>
<td>Deceased</td>
</tr>
<tr>
<td>P16</td>
<td>L988S/Y</td>
<td>20</td>
<td>Middle East</td>
<td>Turkey</td>
<td>Survived</td>
</tr>
<tr>
<td>P17</td>
<td>M854I;L988S/Y</td>
<td>71</td>
<td>European</td>
<td>Italy</td>
<td>Survived</td>
</tr>
</tbody>
</table>

* P10’s brother (not included in the cohort of 1,202 critical patients with critical COVID-19 pneumonia).
GME Variome, Greater Middle Eastern Variome Project
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19


Sci. Immunol. 6, eabl4348.
DOI: 10.1126/sciimmunol.eabl4348

ARTICLE TOOLS
http://immunology.sciencemag.org/content/6/62/eabl4348

SUPPLEMENTARY MATERIALS
http://immunology.sciencemag.org/content/suppl/2021/08/19/6.62.eabl4348.DC1

REFERENCES
This article cites 75 articles, 23 of which you can access for free
http://immunology.sciencemag.org/content/6/62/eabl4348#BIBL

Use of this article is subject to the Terms of Service